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Compensating for insulin resistance  









































































Islet b cell failure and the natural history of T2D. T2D develops in response to overnutriton and lack of physical activity in subjects that have 
underlying genetic and acquired predispositions to both insulin resistance (and/or hyperinsulinemia) and b cell dysfunction. Over time, islet b 
cell compensation for the insulin resistance fails, resulting in a progressive decline in b cell function. As a consequence, subjects progress from 
normal glucose tolerance (NGT) to IGT and finally to established T2D. Even after diagnosis of T2D, b cell function continues to worsen such that 
subjects progress from needing changes in diet/exercise only to requiring oral hypoglycemic agents and eventually insulin for achievement of 
adequate glycemic control. Future therapies will be directed not only to achievement of euglycemia, but also changing the course of the disease 
by reversing the processes of b cell failure.
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Promoting islet compensation  











































































































































Determinants of “susceptible” islets in T2D


















Mechanisms of b cell compensation for insulin resistance. Normally islet b cells respond to insulin resistance by increased secretion through the 
processes of compensation. These include an expansion of b cell mass, increased insulin biosynthesis, and enhanced nutrient secretion coupling 
processes with increased sensitivity to glucose, FFAs, and GLP-1 stimuli. Enhanced glucose utilization, glucose oxidation, anaplerosis/cataple-
rosis, and TG/FFA cycling result in increased production of coupling signals necessary for insulin exocytosis. For expansion of b cell mass, roles 
are evident for increased activity of growth factor signaling pathways, postprandial glucose, and GLP-1 signaling that promote b cell proliferation 
and neogenesis and prevent apoptosis. Furthermore, signaling for growth may occur in response to FFAs, via the FFA receptors (FFAR) and 
via lipid signaling molecules derived from TG/FFA cycling. adr, adrenergic; ANS, autonomic nervous system; chol, cholinergic; CREB, cAMP 
response element–binding protein; DAG, diacylglycerol; GF, growth factor; GLP1R, GLP-1 receptor; GHR, growth hormone receptor; IGFR, 
insulin-like growth factor receptor; IR, insulin receptor, IRS-2, insulin receptor substrate 2; MCF, metabolic coupling factors; npt, neuropeptide; 
PKB, phosphokinase B; PL, phospholipids.
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ivator 1-a (PGC1a) (63), transcription factor	Kruppel-like factor 11	

































(insulin receptor, IRS2, and Akt2), of the MODY gene hepatic nuclear 
factor 4a  (HNF4a), and several glucose metabolism genes were 
reported (69). A novel finding from this study was a 90% reduction 
in the expression of the transcription factor aryl hydrocarbon receptor 
































































Molecular basis of b cell failure:  
mechanisms with initiation roles















Mechanisms of b cell failure in T2D. Islet 
b cell compensation for insulin resistance 
is sustained provided b cells are robust, 
resulting in long-term maintenance of 
NGT. Compensation processes, how-
ever, fail if there are genetic or acquired 
factors that result in susceptible b cells. 
The defect(s) create weak link(s) in the 
compensation process that promote b 
cell dysfunction by mechanisms with 
initiator roles that result in IGT and early 
T2D. Hyperglycemia, once established, 
promotes a further series of mecha-
nisms, under the umbrella of glucotoxic-
ity, that cause severe b cell failure and 
overt and late T2D. AMPK/Mal-CoA, 
AMPK/malonyl-CoA signaling network.
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Mechanisms with progression roles  
in islet b cell damage in T2D
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CoA  synthetases  regulate  fatty  acid  entry  into 
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